

Giancarlo Comi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5740539/publications.pdf>

Version: 2024-02-01

368
papers

39,644
citations

5126

86
h-index

3595

187
g-index

388
all docs

388
docs citations

388
times ranked

24003
citing authors

#	ARTICLE	IF	CITATIONS
1	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	1.8	10
2	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	1.4	37
3	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 608-619.	1.4	13
4	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. <i>Pattern Recognition</i> , 2022, 123, 108403.	5.1	26
5	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.5	31
6	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	1.7	8
7	COVID-19 Severity in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	57
8	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	31
9	Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 105-114.	1.3	1
10	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	2.8	6
11	Intensive Neurorehabilitation and Gait Improvement in Progressive Multiple Sclerosis: Clinical, Kinematic and Electromyographic Analysis. <i>Brain Sciences</i> , 2022, 12, 258.	1.1	6
12	Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. <i>European Journal of Neurology</i> , 2022, 29, 2024-2035.	1.7	6
13	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757.	0.9	10
14	Visual Evoked Potentials to Monitor Myelin Cuprizone-Induced Functional Changes. <i>Frontiers in Neuroscience</i> , 2022, 16, 820155.	1.4	10
15	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636.	1.5	7
16	Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach—perspectives from the International Progressive MS Alliance. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210991.	0.5	0
17	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103909.	0.9	4
18	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1944-1962.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Repetitive Transcranial Magnetic Stimulation With H-Coil Coupled With Cycling for Improving Lower Limb Motor Function After Stroke: An Exploratory Study. <i>Neuromodulation</i> , 2021, 24, 916-922.	0.4	7
20	Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 21-34.	1.4	6
21	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021, 89, 13-23.	2.8	123
22	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	1.4	19
23	Multiple Sclerosis Data Alliance â€“ A global multi-stakeholder collaboration to scale-up real world data research. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102634.	0.9	11
24	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102673.	0.9	20
25	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 347-359.	1.4	41
26	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 331-346.	1.4	26
27	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	1.5	48
28	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	36
29	Diseaseâ€™Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	2.8	370
30	DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S088-S089.	0.6	14
31	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102844.	0.9	19
32	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	4.5	26
33	Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 253-265.	2.8	9
34	DMTs and Covidâ€™19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
35	O67â€™...Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials. , 2021, , .		0
36	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021, 28, 3722-3730.	1.7	12

#	ARTICLE	IF	CITATIONS
37	The 4â€Holeâ€Board Test for Assessment of Longâ€Term Spatial Memory in Mice. <i>Current Protocols</i> , 2021, 1, e228.	1.3	6
38	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5Âµg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. <i>Advances in Therapy</i> , 2021, 38, 4975-4985.	1.3	14
39	Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199085.	0.5	3
40	Apparatus design and behavioural testing protocol for the evaluation of spatial working memory in mice through the spontaneous alternation T-maze. <i>Scientific Reports</i> , 2021, 11, 21177.	1.6	40
41	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1870-e1885.	1.5	168
42	Structural connectivity in multiple sclerosis and modeling of disconnection. <i>Multiple Sclerosis Journal</i> , 2020, 26, 220-232.	1.4	28
43	Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 233-244.	1.4	19
44	Changes in functional and structural brain connectome along the Alzheimerâ€™s disease continuum. <i>Molecular Psychiatry</i> , 2020, 25, 230-239.	4.1	78
45	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2020, 17, 208-217.	2.1	28
46	Large vessel occlusion stroke due to dislodged aortic valve calcification revealed by imaging and histopathology. <i>Journal of the Neurological Sciences</i> , 2020, 408, 116573.	0.3	2
47	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 445-453.	1.7	20
48	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon Î²-1a. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101891.	0.9	4
49	A new electrophysiological non-invasive method to assess retinocortical conduction time in the Dark Agouti rat through the simultaneous recording of electroretinogram and visual evoked potential. <i>Documenta Ophthalmologica</i> , 2020, 140, 245-255.	1.0	2
50	Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis. <i>Clinical Neurophysiology</i> , 2020, 131, 401-405.	0.7	13
51	Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. <i>BMC Neurology</i> , 2020, 20, 364.	0.8	1
52	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	4.9	64
53	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1157-1162.	1.4	50
54	Teaching NeurolImages: Osteolytic intraosseous meningioma causing transcalvarial herniation. <i>Neurology</i> , 2020, 95, e1110-e1111.	1.5	0

#	ARTICLE	IF	CITATIONS
55	Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation. <i>Molecules</i> , 2020, 25, 5403.	1.7	12
56	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	13.9	358
57	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	3.7	56
58	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.3	1
59	Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852096037.	1.4	4
60	Neuro-Retina Might Reflect Alzheimer's Disease Stage. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1455-1468.	1.2	16
61	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024.	3.7	53
62	Functional evolution of visual involvement in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732096347.	0.5	7
63	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102572.	0.9	36
64	The Danger of Walking with Socks: Evidence from Kinematic Analysis in People with Progressive Multiple Sclerosis. <i>Sensors</i> , 2020, 20, 6160.	2.1	3
65	The window of opportunity for treatment of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 262-270.	1.8	27
66	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2020, 9, 443-457.	1.4	4
67	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , 2020, 41, 1647-1650.	0.9	48
68	Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102061.	0.9	2
69	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. <i>Neurological Sciences</i> , 2020, 41, 2843-2851.	0.9	7
70	Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections. <i>Frontiers in Neurology</i> , 2020, 11, 201.	1.1	33
71	Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. <i>Journal of Neurology</i> , 2020, 267, 2272-2280.	1.8	26
72	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , 2020, 43, 635-643.	1.4	20

#	ARTICLE	IF	CITATIONS
73	Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study. JMIR MHealth and UHealth, 2020, 8, e16043.	1.8	31
74	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. Journal of Medical Internet Research, 2020, 22, e19992.	2.1	155
75	Functional and structural plasticity following action observation training in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1472-1487.	1.4	26
76	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	1.4	37
77	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2019, 25, 968-979.	1.4	12
78	Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. Journal of Psychosomatic Research, 2019, 124, 109761.	1.2	17
79	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurology: Neuroimmunology and Neuroinflammation, 2019, 6, e591.	3.1	9
80	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	4.9	191
81	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	4.9	184
82	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	1.8	1
83	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 168-174.	0.9	94
84	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 33, 75-77.	0.9	13
85	Expanding the spectrum of genes responsible for hereditary motor neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1171-1179.	0.9	30
86	Engaging across dimensions of diversity: A cross-national perspective on mHealth tools for managing relapsing remitting and progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 32, 123-132.	0.9	34
87	Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy". Annals of Neurology, 2019, 86, 324-324.	2.8	4
88	Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 449-452.	1.1	1
89	Multispectral MRI with Dual Fluorinated Probes to Track Mononuclear Cell Activity in Mice. Radiology, 2019, 291, 351-357.	3.6	36
90	Survival prediction models in motor neuron disease. European Journal of Neurology, 2019, 26, 1143-1152.	1.7	23

#	ARTICLE	IF	CITATIONS
91	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2019, 85, 606-610.	2.8	30
92	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 155-164.	4.9	63
93	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	0.9	59
94	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 157-167.	0.9	94
95	Added value of multimodal MRI to the clinical diagnosis of primary progressive aphasia variants. <i>Cortex</i> , 2019, 113, 58-66.	1.1	13
96	Brain and cord imaging features in neuromyelitis optica spectrum disorders. <i>Annals of Neurology</i> , 2019, 85, 371-384.	2.8	66
97	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , 2019, 92, e733-e741.	1.5	57
98	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019, 25, 627-636.	1.4	90
99	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 57-59.	0.9	1
100	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 204-216.	1.4	33
101	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 565-573.	1.4	9
102	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 399-407.	1.4	38
103	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 801-810.	1.4	17
104	Cognitive reserve, cognition, and regional brain damage in MS: A 2%-year longitudinal study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 372-381.	1.4	40
105	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 819-827.	1.4	46
106	The CSF p-tau181/A β 242 Ratio Offers a Good Accuracy in Vivo in the Differential Diagnosis of Alzheimer's Dementia. <i>Current Alzheimer Research</i> , 2019, 16, 587-595.	0.7	17
107	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. <i>Radiology</i> , 2018, 288, 234-244.	3.6	40
108	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775336.	1.5	45

#	ARTICLE	IF	CITATIONS
109	<scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 2018, 25, 215-237.	1.7	147
110	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	1.4	458
111	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	4.9	98
112	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	4.9	4,605
113	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	0.5	32
114	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
115	Bi-hemispheric repetitive transcranial magnetic stimulation for upper limb motor recovery in chronic stroke: A feasibility study. Brain Stimulation, 2018, 11, 932-934.	0.7	4
116	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Multiple Sclerosis Journal, 2018, 24, 167-174.	1.4	18
117	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Multiple Sclerosis Journal, 2018, 24, 535-539.	1.4	15
118	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. Multiple Sclerosis Journal, 2018, 24, 459-471.	1.4	105
119	Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1183-1195.	1.4	54
120	Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?. Multiple Sclerosis Journal, 2018, 24, 902-907.	1.4	5
121	Fast progressive lower motor neuron disease is an ALS variant: A two-centre tract of interest-based MRI data analysis. NeuroImage: Clinical, 2018, 17, 145-152.	1.4	35
122	Safety and efficacy of cladribine tablets in patients with relapsing—remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal, 2018, 24, 1594-1604.	1.4	227
123	Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. Neurological Sciences, 2018, 39, 373-376.	0.9	11
124	040–An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A17.1-A17.	0.9	1
125	Letter to the Editor Regarding: A Comprehensive Review on Copemyl™. Neurology and Therapy, 2018, 7, 385-390.	1.4	1
126	The role of clinical and neuroimaging features in the diagnosis of CADASIL. Journal of Neurology, 2018, 265, 2934-2943.	1.8	25

#	ARTICLE	IF	CITATIONS
127	039â€¦Rates of lymphopenia in years 1â€“4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A16.2-A16.	0.9	3
128	067â€¦Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A27.2-A28.	0.9	0
129	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 73-76.	0.9	4
130	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 447-453.	1.0	4
131	Digital epidemiology confirms a latitude gradient of MS in France. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 129-131.	0.9	6
132	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , 2018, 384, 58-60.	0.3	2
133	Long-term safety and tolerability of glatiramer acetate 20 mg in the treatment of relapsing forms of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 247-255.	1.0	24
134	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. <i>Multiple Sclerosis Journal</i> , 2017, 23, 577-587.	1.4	26
135	Subcutaneous interferon Î²-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 285-294.	0.9	38
136	The first year after diagnosis: psychological impact on people with multiple sclerosis. <i>Psychology, Health and Medicine</i> , 2017, 22, 1063-1071.	1.3	23
137	Typical and atypical pathology in primary progressive aphasia variants. <i>Annals of Neurology</i> , 2017, 81, 430-443.	2.8	288
138	Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1864-1874.	1.4	48
139	Evaluation of an optimized [¹⁸ F]fluoroâ€“deoxyâ€“glucose positron emission tomography voxelâ€“wise method to early support differential diagnosis in atypical Parkinsonian disorders. <i>European Journal of Neurology</i> , 2017, 24, 687.	1.7	40
140	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1918-1928.	1.4	13
141	Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1558-1561.	1.4	4
142	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	2.8	34
143	Structural brain abnormalities in patients with vestibular migraine. <i>Journal of Neurology</i> , 2017, 264, 295-303.	1.8	42
144	Structural and functional brain signatures of C9orf72 in motor neuron disease. <i>Neurobiology of Aging</i> , 2017, 57, 206-219.	1.5	54

#	ARTICLE	IF	CITATIONS
145	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 454-461.	1.0	18
146	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 1005-1007.	1.8	2
147	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	13.9	1,322
148	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	13.9	1,324
149	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017, 264, 2436-2449.	1.8	44
150	Brain network connectivity differs in early-onset neurodegenerative dementia. <i>Neurology</i> , 2017, 89, 1764-1772.	1.5	90
151	Cerebrospinal Fluid Amyloid- β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 183-200.	1.2	31
152	â€“Progressive MS â€“ macro viewsâ€™: The need for novel clinical trial paradigms to enable drug development for progressive MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1649-1655.	1.4	3
153	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1600-1613.	1.4	28
154	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731773280.	0.5	22
155	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , 2017, 140, 2814-2819.	3.7	51
156	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017, 89, 1265-1273.	1.5	13
157	Weight gain after subthalamic nucleus deep brain stimulation in Parkinsonâ€™s disease is influenced by dyskinesiasâ€™ reduction and electrodesâ€™ position. <i>Neurological Sciences</i> , 2017, 38, 2123-2129.	0.9	19
158	Benefitâ€“Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , 2017, 77, 1755-1768.	4.9	49
159	Structural connectivityâ€“defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations. <i>Human Brain Mapping</i> , 2017, 38, 6005-6018.	1.9	40
160	Multimodal structural MRI in the diagnosis of motor neuron diseases. <i>NeuroImage: Clinical</i> , 2017, 16, 240-247.	1.4	55
161	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , 2017, 383, 166-168.	0.3	29
162	Pediatric versus adult MS: similar or different?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	32

#	ARTICLE	IF	CITATIONS
163	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , 2017, 38, 361-364.	0.9	8
164	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , 2017, 38, 53-59.	0.9	25
165	Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1194-1203.	1.4	53
166	Brain plasticity in Parkinson's disease with freezing of gait induced by action observation training. <i>Journal of Neurology</i> , 2017, 264, 88-101.	1.8	101
167	Action observation training modifies brain gray matter structure in healthy adult individuals. <i>Brain Imaging and Behavior</i> , 2017, 11, 1343-1352.	1.1	12
168	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.4	41
169	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. <i>Brain Imaging and Behavior</i> , 2017, 11, 1238-1247.	1.1	5
170	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet, The</i> , 2017, 389, 1347-1356.	6.3	252
171	The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2017, 8, 433.	1.1	58
172	Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. <i>Scientific Reports</i> , 2017, 7, 40136.	1.6	38
173	Laquinimod Safety Profile. <i>International Journal of MS Care</i> , 2017, 19, 16-24.	0.4	15
174	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-9.	0.4	18
175	MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 243-253.	1.8	29
176	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , 2016, 23, e39-40.	1.7	2
177	Structural brain correlates of cognitive and behavioral impairment in <sc>MND</sc>. <i>Human Brain Mapping</i> , 2016, 37, 1614-1626.	1.9	84
178	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 944-951.	0.9	88
179	Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1495-1508.	1.2	24
180	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1386-1396.	1.4	118

#	ARTICLE	IF	CITATIONS
181	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , 2016, 361, 184-186.	0.3	2
182	Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 808-810.	4.0	11
183	Optic neuritis in multiple sclerosis. <i>Neurology</i> , 2016, 87, 338-339.	1.5	1
184	Amyloid- β^2 deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	3.7	68
185	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. <i>Human Brain Mapping</i> , 2016, 37, 2293-2304.	1.9	29
186	Cognitive impairment in progressive supranuclear palsy-Richardson's syndrome is related to white matter damage. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 65-71.	1.1	17
187	Surrogate Markers in Multiple Sclerosis. , 2016, , 163-187.		0
188	A review of recent literature on functional MRI and personal experience in two cases of definite vestibular migraine. <i>Neurological Sciences</i> , 2016, 37, 1399-1402.	0.9	27
189	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life " A post hoc analysis of the TEMSO and TOWER studies. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 33-40.	0.9	32
190	Clinical Pre-genetic Screening for Stroke Monogenic Diseases. <i>Stroke</i> , 2016, 47, 1702-1709.	1.0	34
191	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1506-1508.	1.4	41
192	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1315-1326.	1.4	62
193	Assessing response to interferon- β^2 in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016, 87, 134-140.	1.5	98
194	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016, 263, 1727-1735.	1.8	45
195	Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 39-44.	1.7	33
196	Impaired functional integration in multiple sclerosis: a graph theory study. <i>Brain Structure and Function</i> , 2016, 221, 115-131.	1.2	122
197	Noninvasive Neuromodulation in Poststroke Gait Disorders. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 71-82.	1.4	49
198	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	4.9	266

#	ARTICLE	IF	CITATIONS
199	Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1144-1153.	1.4	55
200	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2016, 15, 373-381.	4.9	150
201	Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1621-1625.	1.4	22
202	Brain MR Imaging in Patients with Lower Motor Neuronâ€“Predominant Disease. <i>Radiology</i> , 2016, 280, 545-556.	3.6	32
203	MR Imaging of Brachial Plexus and Limb-Girdle Muscles in Patients with Amyotrophic Lateral Sclerosis. <i>Radiology</i> , 2016, 279, 553-561.	3.6	32
204	Long-term (up to 4.5â€“years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 468-475.	0.9	137
205	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 628-640.	1.4	28
206	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 511-519.	1.4	76
207	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 292-301.	1.4	16
208	Following the Spreading of Brain Structural Changes in Alzheimerâ€™s Disease: A Longitudinal, Multimodal MRI Study. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 995-1007.	1.2	43
209	Ceruloplasmin functional changes in Parkinsonâ€™s disease-cerebrospinal fluid. <i>Molecular Neurodegeneration</i> , 2015, 10, 59.	4.4	35
210	Brain structural and functional connectivity in Parkinson's disease with freezing of gait. <i>Human Brain Mapping</i> , 2015, 36, 5064-5078.	1.9	154
211	Hippocampalâ€“DMN disconnectivity in MS is related to WM lesions and depression. <i>Human Brain Mapping</i> , 2015, 36, 5051-5063.	1.9	58
212	The Communication of Multiple Sclerosis Diagnosis: The Patientsâ€™ Perspective. <i>Multiple Sclerosis International</i> , 2015, 2015, 1-7.	0.4	7
213	Switching from natalizumab to fingolimod. <i>Neurology</i> , 2015, 85, 29-39.	1.5	110
214	White Matter Degeneration in Atypical Alzheimer Disease. <i>Radiology</i> , 2015, 277, 162-172.	3.6	55
215	White matter microstructure abnormalities in pediatric migraine patients. <i>Cephalalgia</i> , 2015, 35, 1278-1286.	1.8	42
216	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249

#	ARTICLE	IF	CITATIONS
217	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. <i>Multiple Sclerosis Journal</i> , 2015, 21, 189-197.	1.4	56
218	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015, 21, 956-959.	1.4	21
219	Differentiation between Subtypes of Primary Progressive Aphasia by Using Cortical Thickness and Diffusion-Tensor MR Imaging Measures. <i>Radiology</i> , 2015, 276, 219-227.	3.6	34
220	Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: Post hoc analysis of the L-arginine trial. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1582-1591.	1.5	7
221	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015, 138, 3275-3286.	3.7	76
222	Thrombolysis with rt-PA for an ischemic stroke in boy treated with Fontan operation. <i>Journal of Pediatric Neurology</i> , 2015, 09, 497-500.	0.0	0
223	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015, 262, 2466-2471.	1.8	4
224	Elevated body temperature is linked to fatigue in an Italian sample of relapsing/remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2015, 262, 2440-2442.	1.8	22
225	Sativex® and clinical neurophysiological measures of spasticity in progressive multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 2520-2527.	1.8	47
226	A multimodal neuroimaging study of a case of crossed nonfluent/agrammatic primary progressive aphasia. <i>Journal of Neurology</i> , 2015, 262, 2336-2345.	1.8	24
227	Oral corticosteroids for multiple sclerosis relapse. <i>Lancet, The</i> , 2015, 386, 937-939.	6.3	7
228	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2015, 289, 62-67.	1.1	20
229	Relapses in patients treated with fingolimod after previous exposure to natalizumab. <i>Multiple Sclerosis Journal</i> , 2015, 21, 786-790.	1.4	26
230	Efficacy of subcutaneous interferon Æ-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 647-653.	0.9	23
231	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 851-858.	0.9	101
232	Position and practical use of fingolimod in Europe. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 19-33.	0.5	6
233	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 705-716.	1.4	295
234	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 147-155.	0.9	57

#	ARTICLE	IF	CITATIONS
235	Deep Repetitive Transcranial Magnetic Stimulation With H-coil on Lower Limb Motor Function in Chronic Stroke: A Pilot Study. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 1141-1147.	0.5	43
236	Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. <i>Journal of the Neurological Sciences</i> , 2014, 342, 167-172.	0.3	20
237	Excitatory Deep Repetitive Transcranial Magnetic Stimulation With H-coil as Add-on Treatment of Motor Symptoms in Parkinson's Disease: An Open Label, Pilot Study. <i>Brain Stimulation</i> , 2014, 7, 297-300.	0.7	38
238	Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. <i>Journal of Neurology</i> , 2014, 261, 267-276.	1.8	117
239	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 247-256.	4.9	476
240	Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 147-155.	1.4	94
241	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 862-870.	1.4	11
242	Resting state functional connectivity alterations in primary lateral sclerosis. <i>Neurobiology of Aging</i> , 2014, 35, 916-925.	1.5	41
243	Multiple sclerosis progression is not associated with birth timing in Italy. <i>Journal of the Neurological Sciences</i> , 2014, 346, 194-196.	0.3	1
244	Neuropsychological features in childhood and juvenile multiple sclerosis. <i>Neurology</i> , 2014, 83, 1432-1438.	1.5	227
245	Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 478.	2.0	24
246	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. <i>Journal of Neurology</i> , 2014, 261, 1781-1788.	1.8	23
247	Peripheral nerve morphogenesis induced by scaffold micropatterning. <i>Biomaterials</i> , 2014, 35, 4035-4045.	5.7	39
248	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 977-986.	4.9	254
249	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.5	2,344
250	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology</i> , The, 2014, 13, 257-267.	4.9	194
251	Disrupted brain connectome in semantic variant of primary progressive aphasia. <i>Neurobiology of Aging</i> , 2014, 35, 2646-2655.	1.5	74
252	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. <i>Human Brain Mapping</i> , 2014, 35, 1710-1722.	1.9	76

#	ARTICLE	IF	CITATIONS
253	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. <i>Journal of Neurology</i> , 2013, 260, 2472-2480.	1.8	35
254	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , 2013, 260, 2023-2032.	1.8	82
255	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013, 260, 1452-1468.	1.8	189
256	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , 2013, 260, 1136-1146.	1.8	46
257	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1082-1091.	0.9	267
258	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo). <i>Journal of Neurology</i> , 2013, 260, 1136-1146.	0.9	16
259	Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1084-1094.	1.4	43
260	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1074-1083.	1.4	87
261	Disease-modifying treatments for progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1428-1436.	1.4	44
262	Cladribine tablets for the treatment of relapsing/remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 123-136.	0.9	24
263	Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of Tuberous Sclerosis Complex. <i>Neuropharmacology</i> , 2013, 67, 1-7.	2.0	40
264	Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study. <i>Neurological Sciences</i> , 2013, 34, 209-215.	0.9	5
265	Extramotor Damage Is Associated with Cognition in Primary Lateral Sclerosis Patients. <i>PLoS ONE</i> , 2013, 8, e82017.	1.1	33
266	Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. <i>Annals of Neurology</i> , 2012, 72, 610-624.	2.8	277
267	Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor. <i>American Journal of Pathology</i> , 2012, 180, 267-274.	1.9	127
268	Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 366, 1000-1009.	13.9	329
269	Sturge-Weber syndrome with an unusual onset in the sixth decade: a case report. <i>Neurological Sciences</i> , 2012, 33, 949-950.	0.9	5
270	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. <i>Lancet Neurology</i> , 2012, 11, 33-41.	4.9	185

#	ARTICLE	IF	CITATIONS
271	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 49-54.	0.9	29
272	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIBine Tablets) Trial. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 55-62.	1.4	109
273	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex [®]), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. <i>European Journal of Neurology</i> , 2011, 18, 1122-1131.	1.7	364
274	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , The, 2011, 10, 520-529.	4.9	204
275	Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. <i>Neurological Sciences</i> , 2011, 31, 299-302.	0.9	52
276	Natalizumab: state of the art and open questions. <i>Neurological Sciences</i> , 2011, 31, 313-315.	0.9	2
277	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group of the Italian Neurological Society. <i>Neurological Sciences</i> , 2011, 32, 351-358.	0.9	17
278	A fatal case of Churg-Strauss syndrome presenting with acute polyneuropathy mimicking Guillain-Barré syndrome. <i>Neurological Sciences</i> , 2011, 32, 937-940.	0.9	10
279	Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2011, 365, 1293-1303.	13.9	842
280	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1344-1350.	0.9	80
281	Neurophysiological correlates of cognitive disturbances in multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 249-253.	0.9	17
282	Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 261-264.	0.9	19
283	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 409-411.	2.8	40
284	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 402-415.	13.9	1,983
285	The contribution of MRI in assessing cognitive impairment in multiple sclerosis. <i>Neurology</i> , 2010, 75, 2121-2128.	1.5	166
286	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 416-426.	13.9	791
287	Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. <i>Multiple Sclerosis Journal</i> , 2010, 16, 197-207.	1.4	149
288	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1360-1366.	1.4	53

#	ARTICLE	IF	CITATIONS
289	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. <i>Neurology</i> , 2009, 73, 1842-1848.	1.5	74
290	250 µg or 500 µg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology</i> , The, 2009, 8, 889-897.	4.9	377
291	Real-life impact of early interferon ^β therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 513-520.	2.8	132
292	Corpus callosum damage and cognitive dysfunction in benign MS. <i>Human Brain Mapping</i> , 2009, 30, 2656-2666.	1.9	99
293	Mitoxantrone: benefits and risks in multiple sclerosis patients. <i>Neurological Sciences</i> , 2009, 30, 167-170.	0.9	69
294	Treatment of multiple sclerosis: role of natalizumab. <i>Neurological Sciences</i> , 2009, 30, 155-158.	0.9	22
295	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009, 286, 109-113.	0.3	23
296	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1503-1511.	6.3	551
297	Definition of responder: introduction. <i>Neurological Sciences</i> , 2008, 29, 209-210.	0.9	1
298	Induction vs. escalating therapy in Multiple Sclerosis: practical implications. <i>Neurological Sciences</i> , 2008, 29, 253-255.	0.9	35
299	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , The, 2008, 371, 2085-2092.	6.3	265
300	Clinically isolated syndrome: the rationale for early treatment. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 234-235.	2.7	16
301	Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2006, 355, 1124-1140.	13.9	996
302	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. <i>Journal of the Neurological Sciences</i> , 2006, 245, 111-116.	0.3	68
303	Early treatment. <i>Neurological Sciences</i> , 2006, 27, s8-s12.	0.9	12
304	Extracorporeal phototherapy in multiple sclerosis. <i>Neurological Sciences</i> , 2006, 27, 3-4.	0.9	2
305	Understanding fatigue in multiple sclerosis: new insights in causes and assessment. <i>Neurological Sciences</i> , 2006, 27, s304-s306.	0.9	5
306	Italian Multiple Sclerosis Database Network. <i>Neurological Sciences</i> , 2006, 27, s358-s361.	0.9	18

#	ARTICLE	IF	CITATIONS
307	Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. <i>Journal of Cell Science</i> , 2006, 119, 3981-3993.	1.2	174
308	Imaging Spinal Cord Damage in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2005, 15, 297-304.	1.0	13
309	Evidence for use of glatiramer acetate in multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 75-76.	4.9	8
310	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. <i>Neurology</i> , 2004, 62, 1432-1434.	1.5	113
311	Multiple sclerosis: pseudotumoral forms. <i>Neurological Sciences</i> , 2004, 25, s374-s379.	0.9	43
312	Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. <i>Human Brain Mapping</i> , 2004, 21, 108-117.	1.9	96
313	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2004, 364, 1489-1496.	6.3	246
314	Cognitive dysfunction in patients with mildly disabling relapsing/remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. <i>Journal of the Neurological Sciences</i> , 2002, 195, 103-109.	0.3	208
315	A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. <i>Journal of Neurology</i> , 2002, 249, 1370-1377.	1.8	151
316	<i>Neurophysiology</i> , , 2002, , 25-33.		0
317	The role of non-conventional MR techniques to study multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2001, 186, S3-S9.	0.3	15
318	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet</i> , The, 2001, 357, 1576-1582.	6.3	1,025
319	Physiopathology and treatment of fatigue in multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 174-179.	1.8	165
320	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 290-297.	2.8	695
321	Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 415-416.	2.8	32
322	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. , 2001, 49, 290.		19
323	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. <i>Annals of Neurology</i> , 2001, 49, 290-7.	2.8	224
324	Whole brain volume changes in patients with progressive MS treated with cladribine. <i>Neurology</i> , 2000, 55, 1714-1718.	1.5	124

#	ARTICLE	IF	CITATIONS
325	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2000, 247, 960-965.	1.8	51
326	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. <i>Journal of Neurology</i> , 2000, 247, 506-509.	1.8	122
327	Prognosis-modifying therapy in multiple sclerosis. <i>Neurological Sciences</i> , 2000, 21, S893-S899.	0.9	6
328	Magnetization transfer imaging to monitor the evolution of MS. <i>Neurology</i> , 2000, 55, 940-946.	1.5	145
329	Chapter 45 Electrophysiological correlates of dementia. <i>Supplements To Clinical Neurophysiology</i> , 2000, 53, 331-336.	2.1	2
330	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 192-198.	0.9	101
331	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. <i>Journal of the Neurological Sciences</i> , 2000, 172, S63-S66.	0.3	21
332	Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. <i>Neurology</i> , 1999, 52, 588-588.	1.5	241
333	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 1999, 17, 985-988.	1.0	8
334	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. <i>Journal of Neurology</i> , 1999, 246, 97-106.	1.8	9
335	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1999, 171, 130-134.	0.3	15
336	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1999, 171, 135-144.	0.3	48
337	Introduction. <i>Neurological Sciences</i> , 1999, 20, S227-S228.	0.9	0
338	Neurophysiological imaging techniques in dementia. <i>Neurological Sciences</i> , 1999, 20, S265-S269.	0.9	10
339	The Italian multicentre study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. <i>Italian Diabetic Neuropathy Committee. Electroencephalography and Clinical Neurophysiology Supplement</i> , 1999, 50, 546-52.	0.0	2
340	Proinflammatory cytokines regulate antigen-independent T-cell Activation by two separate calcium-signaling pathways in multiple sclerosis patients. <i>Annals of Neurology</i> , 1998, 43, 340-349.	2.8	44
341	Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1998, 43, 809-814.	2.8	356
342	Event-Related desynchronization to contingent negative variation and Self-Paced movement paradigms in Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 653-660.	2.2	61

#	ARTICLE	IF	CITATIONS
343	Neuromyotonia, systemic lupus erythematosus and acetylcholine-receptor antibodies. <i>Journal of Neurology</i> , 1998, 245, 182-185.	1.8	3
344	Treatment of chronic inflammatory demyelinating polyneuropathy. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, 261-269.	0.1	1
345	EEG correlates of cognitive impairment in MS. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, S413-S417.	0.1	4
346	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. <i>Neurology</i> , 1998, 50, 1601-1608.	1.5	253
347	Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1998, 4, 260-265.	1.4	25
348	Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. <i>American Journal of Neuroradiology</i> , 1998, 19, 223-9.	1.2	51
349	Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. <i>Multiple Sclerosis Journal</i> , 1997, 3, 93-97.	1.4	6
350	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. <i>Brain</i> , 1997, 120, 2059-2069.	3.7	1,077
351	Axonal neuropathy associated with interferon- β treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells. <i>Acta Neuropathologica</i> , 1997, 94, 504-508.	3.9	24
352	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. <i>Journal of Neurology</i> , 1997, 244, 266-270.	1.8	153
353	Functional Basis of Memory Impairment in Multiple Sclerosis: A [18F]FDG PET Study. <i>NeuroImage</i> , 1996, 4, 87-96.	2.1	127
354	Interferon beta treatment in multiple sclerosis: the European clinical trials. <i>Multiple Sclerosis Journal</i> , 1996, 1, 317-320.	1.4	0
355	Brain MRI follow-up of patients with persistent isolated optic neuritis. <i>European Journal of Neurology</i> , 1996, 3, 36-39.	1.7	2
356	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. <i>Journal of Neurology</i> , 1996, 243, 502-505.	1.8	115
357	Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. <i>Neurology</i> , 1996, 46, 379-384.	1.5	124
358	Quantitative assessment of MRI lesion load in multiple sclerosis: A comparison of conventional spin-echo with fast fluidattenuated inversion recovery. <i>Brain</i> , 1996, 119, 1349-1355.	3.7	164
359	Clinical utility of evoked potentials in patients infected with human immunodeficiency virus. <i>Electroencephalography and Clinical Neurophysiology Supplement</i> , 1996, 46, 85-93.	0.0	2
360	Neurophysiologic Studies and Cognitive Function in Congenital Hypothyroid Children. <i>Pediatric Research</i> , 1995, 37, 736-740.	1.1	20

#	ARTICLE	IF	CITATIONS
361	A Magnetization Transfer Imaging Study of Normal-Appearing White Matter in Multiple Sclerosis. <i>Neurology</i> , 1995, 45, 478-482.	1.5	353
362	Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1995, 132, 222-227.	0.3	167
363	Heterogeneity of autoantibodies in stiff-man syndrome. <i>Annals of Neurology</i> , 1993, 34, 57-64.	2.8	121
364	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1993, 115, S66-S73.	0.3	95
365	Brain Stem Magnetic Resonance Imaging and Evoked Potential Studies of Symptomatic Multiple Sclerosis Patients. <i>European Neurology</i> , 1993, 33, 232-237.	0.6	27
366	Correlation between multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. <i>Journal of Neurology</i> , 1989, 236, 4-8.	1.8	40
367	Visual evoked potentials in diabetic teen-agers: influence of metabolic control and relationship with peripheral neuropathy. <i>Metabolic, Pediatric, and Systemic Ophthalmology</i> , 1986, 9, 85-7.	0.0	7
368	Time-frequency analysis of event-related brain potentials. , 0, , .		0